RHEUMATRACE
Live / Registered — Registered (as of 10 Feb 2026)
What this means for you
Registered since 10 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79392510
- Registration number
- 8131504
- Mark type
- Stylized text
- Filed
- 19 Sept 2023
- Published for opposition
- 23 Dec 2025
- Registered
- 10 Feb 2026
- Attorney of record
- Bradley M. Stohry
Goods and services
- Class 042 — Scientific and technological services: Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; medical and scientific research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; development services in the field of diagnostic preparations, equipment and tests; advice, information and assistance relating to the foregoing
Owner
Prosecution history
- 10 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 23 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Dec 2025 — PUBLISHED FOR OPPOSITION
- 17 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Nov 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 12 Sept 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 27 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 27 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 12 Jun 2025 — NOTIFICATION OF SUBSEQUENT FINAL EMAILED
- 12 Jun 2025 — SUBSEQUENT FINAL EMAILED
- 12 Jun 2025 — SUBSEQUENT FINAL REFUSAL WRITTEN